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Purpose of review:  The oral cavity is one of the main gateways to the whole body and 2 
leads to the gastrointestinal tract.  Both oral cavity and gastrointestinal tract have 3 
complex ecosystems of microorganisms called microbiota.  Recent studies have showed 4 
that altered local microbiome in human, such as gut microflora, is associated with various 5 
systemic diseases.  This review focuses on the association between the microbiota at 6 
local sites, such as gut and oral cavity, and the systemic diseases, especially nutrition-7 
associated metabolic disorder, such as obesity and/or diabetes. 8 
Recent findings:  The gut microbiota has a potential for regulation in host immune 9 
system and metabolisms, such as energy, glucose and lipid, and is therefore an additional 10 
contributing environmental factor to the pathophysiology of obesity and diabetes as well 11 
as gut infectious inflammatory diseases.  In addition, oral microorganisms play 12 
important roles as reservoirs for exacerbation of gut diseases and altered oral microbial 13 
profiles causing periodontal diseases, one of common oral infectious diseases, has been 14 
also associated with several systemic diseases including diabetes. 15 
Summary:  It is necessary to consider that impaired oral microbiota, called oral 16 
dysbiosis, may affect the metabolic disorders leading to obesity and diabetes in addition 17 
to the gut inflammatory diseases via alteration of gut microflora.  The relevance of oral 18 
microflora to gut dysbiosis leading to nutrition-associated metabolic disorder should be 19 
addressed as future investigations. 20 




The microbiota, a complex ecosystem of microorganisms mainly consisting of bacteria, 2 
has been considered to play important roles in metabolic functions, such as the regulation 3 
of several biochemical and physiological mechanisms via the production of various 4 
metabolites and substances (1).  As the good correlation with the human health, the 5 
microbiota has several beneficial activities, such as anti-inflammatory and anti-6 
carcinogenic actions.  For instance, over 70% of the microbiota living in the 7 
gastrointestinal tract, which is an entry site for nutrients and an encounter site with the 8 
immune system, has a mutually beneficial relationship with host (1, 2).  However, the 9 
alterations of microbiome have been also considered to play critical roles in the cause and 10 
development of various systemic diseases, especially metabolic disorder such as obesity 11 
and diabetes (1, 3).  Moreover, it has been indicated that the disturbance and imbalance 12 
in the microbiome result in infectious inflammatory diseases, such as intestinal infectious 13 
diseases and periodontal disease, at many sites in human body.  Therefore, it has been 14 
considered that the microbiota at various sites, such as mouth, gut and skin, in human 15 
affects health or disease (2).  The mouth is the gateway leading to gut via esophagus as 16 
the passageway for food and the microbiota of oral cavity has the second most abundant 17 
of microflora after gastrointestinal tract (4).  To prevent metabolic diseases caused by 18 
the microbiota modifications and to development novel therapeutic strategies for these 19 
disorders, the clarification of their pathological mechanisms and the link between the 20 
microflora and metabolic diseases is important and required.  As two major microbiota 21 
in human body, this review focuses on both gut and oral microflorae and provides the 22 
current understanding of their association with nutrition-associated metabolic disorder, 23 
such as obesity and/or diabetes, and gut inflammatory diseases.  24 
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Gut microbiota 1 
The human gut harbors trillions of microbes, which form a symbiotic relationship with 2 
the host and play a vital role in both health and disease.  This ‘‘gut microbiota’’ makes 3 
up bacterial complex community that interacts with each other, and it modulates various 4 
biological processes of essential factors in the host for health (5).  The diverse of gut 5 
microbiota is predominantly composed of four major phyla of bacteria, namely 6 
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria (6).  Especially, the most 7 
popular phyla are the Firmicutes and Bacteroidetes, which account for 80% of the whole 8 
microbiota (7-9).  The phylum of bacteria Firmicutes, mainly consisted of Gram-9 
positive bacteria, includes the genera Lactobacillus (Gram-positive), Eubacterium 10 
(Gram-positive), and Clostridium (Gram-positive).  On the other hand, the phylum 11 
Bacteroidetes formed by Gram-negative bacteria, includes the genera Bacteroides and 12 
Prevotella.  The remainder minor proportions are formed by other phyla, such as 13 
Proteobacteria (Gram-negative, in particular genus Escherichia), Actinobacteria (Gram-14 
positive, in particular genus Bifidobacteriium), Fusobacteria (Gram-negative), 15 
Spirochaetes (Gram-negative), Verrucomicrobia (Gram-negative) and Lentispherae 16 
(Gram-negative) (10-12). 17 
   The new critical association of gut microbiota on several metabolisms is found in the 18 
last decade.  In the recent studies, the biological roles in the gut microbiome, such as 19 
modulating juvenile growth (13), maturation of the immune system (14), and modulation 20 
of glucose and lipid metabolism (15), have revealed dramatically.  Those studies make 21 
sure the microbiome participation in homeostatic regulation about different tissues in 22 
human body (16).  Therefore, the gut microbiota is regarded as a one of main factor for 23 
health control and maintenance.  However, while the balance of gut microbiota is 24 
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disrupted, this alterations can lead to attenuation of immunologic regulation and the 1 
development of disease including Clostridium difficile infection (17), inflammatory 2 
bowel disease (IBD) (18, 19), irritable bowel syndrome (20, 21), asthma (22), obesity 3 
(23) and diabetes (24, 25). 4 
 5 
Gut microbiota and antibiotic administration 6 
Antibiotics administration inducing disorder of gut microbiota is well-established model 7 
in microbiota related disease.  Clostridum difficile, which is a Gram-positive toxin and 8 
spore producing anaerobic bacteria, is a one of the normal gut microbiota and members 9 
of Firmicutes.  Clostridum difficile infection (CDI) is a main infectious disease in 10 
nosocomial infection (26). During the CDI, Ruminococcaceae, Lachnospiraceae, 11 
Bacteroides, and Porphyromonadaceae were absent in the patient with diarrhea, 12 
compared with healthy control (17).  Those changing of microbiota are more 13 
pronounced in recurrent CDI patient (27), and recurrent CDI leads to increased abundance 14 
of Proteobacteria, and decreased abundances of Bacteroidetes and Firmicutes (28).  On 15 
the antibiotics administration inducing disorder of gut microbiota, the bio-conversion of 16 
primary bile acid to secondary bile acids is regarded as a one of the proposed mechanism.  17 
Primary bile acid promotes a germination of Clostridum difficile spores, whereas 18 
secondary bile acids attenuate vegetating of Clostridum difficile growth (29).  As a result, 19 
there is a significant reduction in microbial bio-conversion of primary bile acid into 20 
antimicrobial secondary bile acids, leading to reduced inhibition of Clostridum difficile 21 
vegetative growth, allowing Clostridum difficile outgrowth and colonization of the empty 22 
niches, leading to higher susceptibility of host toward CDI (30).  The bacterial complex 23 
community of gut microbiota is vitally important to providing colonization resistance to 24 
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CDI.  Therefore, antibiotics administration leads a changing of gut microbiota and 1 
increases the risk of CDI (31). 2 
 3 
Gut microbiota and gut infectious disease 4 
Similar to the CDI, the condition of gut microbiota also associates with infection of 5 
enteropathogenic bacteria.  Recent studies investing the relationship between 6 
enteropathogenic bacteria and the resident microbiota have developed to illuminate how 7 
these pathogens outmanoeuvre the host defenses.  8 
The composition of the gut microbiota is impacted by host diet or lifestyle.  Nutrient 9 
influences its availability in the gut and changes the composition of the gut microbiota.  10 
Pathogenic bacteria compete against commensal bacteria for nutrients and colonization 11 
within the gut (32, 33).  The members of gut microbiota, such as Bacterioidetes, 12 
Firmicutes, and Acinobacteria phyla, break down several complexes of dietary 13 
carbohydrates.  These gut bacteria produce short-chain fatty acids (SCFAs), particularly 14 
acetate, propionate, and butyrate (34).  Those metabolites are also important for not only 15 
energy sources that aid host cell differentiation or nutrient absorption by the colonic 16 
epithelial cells, but also attenuation of pathogenic bacterial colonization and infection that 17 
induce gastrointestinal disease (33, 35).  Indeed, regarding enteric food-borne pathogens, 18 
such as Enterohemorrhagic Eschrichia coli (EHEC), mice fed with acetylated starch or 19 
co-infected with Bifidobacterium spp., can produce enough acetate, have increased 20 
bacterial acetate levels in their feces, leading the protection against an initial EHEC 21 
colonization (36).  Also, in Salmonella enteria serovar Typhimurium infection, major 22 
pathogens of food-borne disease leading gastroenteritis, presence of Bacterioides 23 
producing the short-chain fatty acid propionate in their feces directly inhibits S. 24 
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Typhimurium growth and colonization in mice (37).  1 
Therefore, the condition of gut microbiota plays a key role in resistance and 2 
tolerance of gastrointestinal infectious disease, and the balance between commensal and 3 
potentially pathogenic bacteria is a central element of human health. 4 
 5 
Gut microbiota and obesity 6 
Obesity is a consequence of an imbalance of energy intake and energy expenditure.  In 7 
early studies of germ-free rodents, energy absorption, a capacity to harvest energy from 8 
the diet, is clearly increased by exposure to the gut microbiota and this trait is 9 
transmissible (15, 38, 39).  Interestingly, the colonization of germ-free mice with an 10 
obese microbiota caused significantly greater increase in total body fat than that with a 11 
lean microbiota, indicating that the gut microbiota is an additional contributing 12 
environmental factor to the pathophysiology of obesity by influencing energy intake from 13 
the diet and energy storage in the host (39).  Regarding the association between gut 14 
microbes and nutrient energy adsorption in human, the proportional representation of 15 
Firmicutes and Bacteroidetes correlated positively and negatively with stool energy loss 16 
in lean individuals, respectively (40).  These changes, an increase in the ratio of 17 
Firmicutes/Bacteroidetes, were also observed in individuals with obesity compared with 18 
in their lean counterparts (41, 42).  In addition, recent interesting findings indicate that 19 
the gut microbiota may regulate feeding patterns involved in the gut-brain axis via 20 
endocrine hormones, including gastric inhibitory peptide, glucagon-like peptide 1, 21 
peptide YY, leptin, and cholecystokinin (43-47).  Moreover, Kaelberer et al. discovered 22 
that there is a direct neural connection from the intestine to the brain in mice (48).  In 23 
contrast to the energy intake, few reports have investigated energy expenditure and the 24 
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gut microbiota.  Kocelak et al. reported that resting energy expenditure (REE) expressed 1 
on the body surface (kcal/m2/h) was positively correlated with the total bacterial count (r 2 
= 0.25, p < 0.05), Bacteroides count (r = 0.24, p < 0.05) and Bacteroides to Firmicutes 3 
rate (r = 0.26, p < 0.05), while negatively with the percentage of Firmicutes colonies (r = 4 
–0.24, p < 0.05) in 50 obese and 30 lean healthy weight stable subjects (49).  However, 5 
none of these correlations were observed in multiple regression analysis.  These reports 6 
and other reviews suggest that the gut microbiota has a potential for regulation in host 7 
energy metabolism (43, 50-52) but their extent in human should be further investigated 8 
in more detail.  9 
 10 
Gut microbiota and diabetes 11 
In addition to obesity as a metabolic disease linked to an altered gut microbiota, the 12 
association between type 2 diabetes, which is the most prevalent endocrine disease 13 
worldwide, and gut microbiota as an environment factor has also been focused and some 14 
gut microbial markers are suggested to be useful for classifying type 2 diabetes (24, 25).  15 
As a result of a cohort study and cross sectional studies of type 2 diabetic patients in 16 
China and Europe, the proportion of butyric acid-producing bacteria, including Roseburia, 17 
Clostriiales sp. SS3/4 and Faecalibacterium prausnitzii, is low in the intestinal flora of 18 
type 2 diabetic patients (24, 25, 53).  Possible mechanisms, which involved in the 19 
signaling of butyrate and other short chain fatty acid and diabetes, were provided in 20 
several reviews (43-46, 54).  In addition, the abundance of Akkermansia muciniphila, 21 
butyrate-producing and mucin-degrading microbe, was enriched reduced in type 2 22 
diabetic patients and negatively correlated with homeostasis model assessment (HOMA) 23 
insulin index (24, 53, 55, 56).  Recently, Udayappan et al. reported that Gram-negative 24 
Ralstonia pickettii levels are higher in impaired glucose tolerance patients and type 2 25 
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diabetic patients than that of normal glucose tolerance subjects (57).  Both A. 1 
muciniphila and R. pickettii could also control the intestinal barrier function in mice (57-2 
59).  Impaired intestinal barrier function and subsequent increased endotoxemia are 3 
observed in obese and diabetic subjects (60-62).  Moreover, an intervention study 4 
consisted of a 6-week calorie restriction (CR) in overweight and obese adults revealed 5 
that individuals with higher baseline A. muciniphila displayed greater improvement in 6 
insulin sensitivity markers and other clinical parameters after intervention of the CR, 7 
suggesting that A. muciniphila is associated with a healthier metabolic status and better 8 
clinical outcomes after CR in overweight/obese adults (56).  A similar result was drawn 9 
in type 2 diabetic patients whom treated by antidiabetic drug, metformin (63).  In 10 
contrast to the insulin resistance, the regulatory activity of the gut microbiome on insulin 11 
secretion was only reported in mice (64).  Since both the amount and action of insulin 12 
insufficiency are the cause of diabetes mellitus, investigation of their relationship with 13 
the gut microbiota, especially in humans, has been much awaited in more detail. 14 
Recently, the modification of the gut microbiota has been attempted to be used in 15 
methods of treating obesity and diabetes.  Fecal microbiota transplantation is one of 16 
treating methods for obesity and/or diabetes that infusing intestinal microbiota from lean 17 
donors to recipients with obese and diabetic subjects (65-67).  Bariatric surgery is also 18 
gathering attention because of its dramatic improvement of metabolic parameters (67, 68).  19 
Structural changes of gastrointestinal tract induce changes in the gut environment, 20 
therefore, subsequent reconfiguration of the gut microbiota and functional changes may 21 
cause after this surgery.  Pre- and pro-biotics are traditional approaches for regulating 22 
the gut microbiota.  However, there is a lack of evidence for the impact of probiotics on 23 
fecal microbiota composition in healthy adults or obese subjects (69, 70).  Of course 24 
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there are some good results (71-73), but the total number of samples, and the quality of 1 
methodology should be improved to draw definitive conclusions.  These inconsistent 2 
results may come from a person-specific gut microbiota which determines resistance to 3 
probiotics and its effects (74). 4 
 5 
Involvement of oral microflora in gut diseases 6 
The oral cavity is one of the main gateways to the whole body (75).   Oral microflora 7 
colonizing in oral cavity comprises approximately 700 microbial species and is associated 8 
with its complex ecological environment (4, 75).  Healthy oral microbiome is 9 
maintained by good habitats, such as oral hygiene and food intake, and keeps the oral 10 
cavity healthy, but it has been reported that the disruption of good oral ecosystem by 11 
various triggers, such as tobacco, alcohol, stress, hormonal alteration, puberty, poor oral 12 
care, diabetes and oral inflammatory conditions, leads to dysbiosis and results in various 13 
systemic diseases as well as oral diseases (4, 76).  Especially, as regards the nutrition, it 14 
has been suggested that core oral microbiome may be altered by diet much containing 15 
carbohydrate and protein (4).  Oral microorganisms living in the oral cavity have been 16 
shown to have the interactive roles with human host cells and direct effects on the 17 
physiology, metabolism and immune responses in human (4, 76-78).  Besides foods, 18 
saliva containing oral microorganisms gets into the stomach and intestinal tract, and air 19 
goes to the lungs and trachea in one direction via the mouth.  Regarding with this 20 
concept, it has been considered that predominant members of oral microbiome could 21 
spread to the whole body from the mouth and colonize the far areas, such as gut, after 22 
reaching to various organs (79).  For instance, the association between disturbances of 23 
the oral microbiome and various systemic diseases, such as diabetes, gastric ulcer, obesity, 24 
cancer, autoimmune diseases, acquired immune deficiency syndrome, endocarditis and 25 
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cardiovascular disease, has been reported (4, 80, 81).  It has been also reported that the 1 
patients with rheumatoid arthritis or IBD have altered oral microbiome (82, 83).  2 
Another study has reported that over 50% of the species enriched in the gut microbiota of 3 
the patients with liver cirrhosis are buccal origin microbial species, suggesting the 4 
invasion of oral microorganisms to gastrointestinal tract (84).  In addition to the 5 
increasing evidence links the gut microbiota with colorectal cancer, one recent study has 6 
shown that a higher abundance of Fusobacterium spp. is found in human colonic adenoma 7 
tissues and in stool samples from colorectal adenoma and carcinoma patients and 8 
Fusobacterium nucleatum selectively recruits tumor-infiltrating immune cells, which can 9 
promote tumor progression, suggesting Fusobacteria generate a pro-inflammatory 10 
microenvironment leading to colorectal neoplasia progression through modulation of the 11 
host immune reaction (85).  A review article also indicated the association between the 12 
domination of F. nucleatum, one of late colonizers in oral cavity and periodontal disease-13 
related bacteria, and gut diseases, such as colorectal cancer and IBD (86).  Periodontal 14 
diseases, one of common oral infectious diseases, are characterized as altered oral 15 
microbial profiles with higher levels of periodontal pathogens, such as Porphyromonas 16 
gingivalis, and disturbed host-microorganism interaction (75) and has been also 17 
associated with several systemic diseases such as diabetes, cerebrovascular diseases and 18 
atherosclerosis.  In vivo experiment using mice model demonstrated that oral 19 
administration of P. gingivalis, one of major periodontal pathogens, alters ileal microbiota 20 
related to systemic inflammatory changes (87).  Dental caries, another in 2 major oral 21 
infectious diseases, is mainly caused by the infection with Streptococcus mutans.  22 
Regarding the involvement of dental caries-related pathogen in the pathology of gut 23 
diseases, it has been reported that the detection frequency of the specific S. mutans strains 24 
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with collagen-binding protein in oral samples of ulcerative colitis patients was 1 
significantly higher than in healthy subjects and increased interferon- in liver, where is 2 
the target organ for S. mutans, is the real trigger of the inflammatory cascade in oral 3 
bacteria-induced aggravation of colitis (88).  This study finally concluded that the 4 
infection with highly virulent specific types of S. mutans is a potential risk factor for the 5 
aggravation of ulcerative colitis, a major IBD.  Moreover, it has been reported that the 6 
concomitant reduction of salivary flow and intraoral pH could predispose to intraoral 7 
colonization with enterobacterial species, such as Klebsiella pneumonia, suggesting that 8 
periodontal pocket plays a significant role as a reservoir for enterobacteria to increase the 9 
risk of gut colonization (89, 90).  These findings have implicated that the relationship 10 
between oral and gut ecological systems affects several chronic infectious and/or 11 
inflammatory diseases.  In this viewpoint, the experiment using susceptible mice 12 
demonstrated that multiple antibiotics-resistant Klebsiella species colonizing in the gut 13 
from the salivary microbiota increase T helper 1 cells and strongly induce gut 14 
inflammation (91).  Another study demonstrated that H. pylori, which is considered to 15 
be responsible for gastritis and peptic ulcers and is a risk factor for gastric cancer, was 16 
detected frequently in the oral microbiota of subjects with periodontitis, suggesting that 17 
periodontal pocketing and inflammation may favor the colonization by this species (92). 18 
Recent findings suggest that oral microorganisms play important roles as reservoirs 19 
for exacerbation of gut diseases and understanding of the change in microbial flora may 20 
lead to the identification of biomarkers for diagnosing the microbiome-associated 21 
diseases (93, 94).  Moreover, in recent years, some therapeutic and pharmacologic 22 
companies have tried to develop a drug and probiotic bacteria based on oral and 23 
gastrointestinal microbiome for the treatment of various diseases instead of antibiotics 24 
13 
 
having the possibility of generating multidrug resistant microorganisms which is the 1 
world-wide problem in the medical field.  Regarding the periodontal medicine, a new 2 
concept meaning the interplay of oral dysbiosis leading to prolonged chronic 3 
inflammatory infectious diseases, such as periodontitis, and gut dysbiosis should be 4 
addressed as future investigations. 5 
 6 
Conclusions 7 
Microbiome in human has the important roles of homeostatic regulation to maintain 8 
human health.  The alteration of local microbiome in oral cavity and gut is associated 9 
with various systemic diseases.  Table 1 summarizes the changes and features in the gut 10 
microflora in subjects with nutrition-associated metabolic disorder and oral infectious 11 
diseases.  The changes of gut microbiota cause several altered metabolisms leading to 12 
obesity and diabetes as well as gut infectious inflammatory diseases.  In addition, the 13 
disturbance of oral microbiota causes oral inflammatory diseases, such as periodontal 14 
diseases which is strongly associated with various systemic diseases including diabetes.  15 
It has been recently indicated that oral microorganisms play important roles as reservoirs 16 
for exacerbation of gut diseases.  Therefore, it has been suggested the possibility that 17 
impaired oral microbiota, called oral dysbiosis, alters gut microflora having biological 18 
and metabolic roles such as energy intake from the diet, and then affects the nutrition 19 
associated-metabolic disorders leading to obesity and diabetes in addition to the gut 20 
inflammatory diseases.  The further investigations focused on the relevance of oral 21 
microflora with the nutrition associated-metabolic disorder are should be needed.  22 
 23 
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Table 1  The changes and features in the gut microflora in subjects with nutrition-associated metabolic disorder, such as obesity and 
diabetes, and with oral infectious diseases, such as periodontal disease and dental caries. 
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